Form 4: MoonLake Immunotherapeutics Executive Sells Shares
Insider Transaction (Form 4)
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, sold 52,448 shares of common stock on July 21, 2026.
Summary
- Open-market sale: disposed of 50,000 Class A ordinary shares, par value $0.0001 per share at $20.02 ($1,001,000) on July 21, 2026; holds 2,714,746 after (Indirect).
- Open-market sale: disposed of 2,448 Class A ordinary shares, par value $0.0001 per share at $20.00 ($48,960) on July 22, 2026; holds 2,712,298 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,049,960 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Kristian Reich — Officer (Chief Scientific Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-21 | Open-market sale | Class A ordinary shares, par value $0.0001 per share | 50,000 | $20 | $1.0M | 2,714,746 |
| 2026-07-22 | Open-market sale | Class A ordinary shares, par value $0.0001 per share | 2,448 | $20 | $49.0K | 2,712,298 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-21 | Open-market sale (50,000 shares) |
| 2026-07-22 | Open-market sale (2,448 shares) |
Keywords
insider transaction, Form 4, MLTX, MoonLake Immunotherapeutics, bearish, Kristian Reich
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.